Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 13 of 15

 
 

Sanofi (NASDAQ:SNY)

Consensus Rating
Moderate Buy
Rating Score
2.6
Ratings Breakdown
2 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$57.50 (0.2% Downside)

About Sanofi

Sanofi logoSanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
9/17/2024CitigroupUpgradeStrong-Buy
7/26/2024ArgusBoost Price TargetBuy ➝ Buy$55.00 ➝ $60.00
1/23/2024Morgan StanleyInitiated CoverageEqual Weight$55.00
12/5/2023JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
10/30/2023Stifel NicolausDowngradeBuy ➝ Hold
9/5/2023Berenberg BankUpgradeHold ➝ Buy
7/14/2023HSBCInitiated CoverageBuy
4/28/2023Deutsche Bank AktiengesellschaftDowngradeHold ➝ Sell
3/27/2023ArgusBoost Price TargetBuy$55.00 ➝ $60.00
3/27/2023BarclaysUpgradeEqual Weight ➝ Overweight
 

Who are Nvidia’s New Silent Partners? (Ad)

Nvidia knows it can’t stand still as AI continues to grow at an exponential rate. That’s why CEO Jensen Huang consistently has his company ahead of the curve when it comes to artificial intelligence. Nvidia’s added $2 trillion in market cap in 2024.

I call these Nvidia’s “Silent Partners.”